Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Sarcoma Unit, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Turin, Italy.
Cancer Gene Ther. 2023 Sep;30(9):1285-1295. doi: 10.1038/s41417-023-00637-8. Epub 2023 Jun 23.
Ewing sarcoma (EWS) is a challenging pediatric cancer characterized by vast intra-tumor heterogeneity. We evaluated the RNA-binding protein IGF2BP3, whose high expression correlates with a poor prognosis and an elevated tendency of metastases, as a possible soluble mediator of inter-cellular communication in EWS. Our data demonstrate that (i) IGF2BP3 is detected in cell supernatants, and it is released inside extracellular vesicles (EVs); (ii) EVs from IGF2BP3-positive or IGF2BP3-negative EWS cells reciprocally affect cell migration but not the proliferation of EWS recipient cells; (iii) EVs derived from IGF2BP3-silenced cells have a distinct miRNA cargo profile and inhibit the PI3K/Akt pathway in recipient cells; (iv) the 11 common differentially expressed miRNAs associated with IGF2BP3-positive and IGF2BP3-negative EVs correctly group IGF2BP3-positive and IGF2BP3-negative clinical tissue specimens. Overall, our data suggest that IGF2BP3 can participate in the modulation of phenotypic heterogeneity.
尤文肉瘤(EWS)是一种具有巨大肿瘤内异质性的儿童癌症。我们评估了 RNA 结合蛋白 IGF2BP3,其高表达与预后不良和转移倾向增加相关,作为 EWS 细胞间通讯的可能可溶性介质。我们的数据表明:(i)IGF2BP3 可在细胞上清液中检测到,并在细胞外囊泡(EVs)中释放;(ii)IGF2BP3 阳性或 IGF2BP3 阴性 EWS 细胞的 EVs 可相互影响 EWS 受者细胞的迁移,但不影响其增殖;(iii)源自 IGF2BP3 沉默细胞的 EVs 具有独特的 miRNA 载物组,并抑制受者细胞中的 PI3K/Akt 通路;(iv)与 IGF2BP3 阳性和 IGF2BP3 阴性 EVs 相关的 11 个常见差异表达 miRNA 可正确将 IGF2BP3 阳性和 IGF2BP3 阴性的临床组织标本分组。总体而言,我们的数据表明 IGF2BP3 可以参与表型异质性的调节。